|
|
|
|
|
|
|
|
|
|
|
01.12.25 - 02:06
|
Research Insight: Gemini threatens OpenAI′s AI crown: Ecosystem advantage signals strategic shift in tech landscape (Digitimes)
|
|
|
Google has launched Gemini 3, a new generative AI model that has quickly outperformed competing models, including OpenAI's recently released GPT-5.1, across most AI benchmark leaderboards. Launched on November 19, Gemini 3 introduces several novel features such as Deep Think mode, Nano Banana, and Antigravity, and is supported by Google's seventh-generation TPU Ironwood hardware unveiled the same month. This marks a strategic shift for Google from a defensive to an offensive approach in the AI arena....
|
|
|
28.11.25 - 05:06
|
Meta′s Google TPU shift opens new AI supply chain for Taiwan PCB makers (Digitimes)
|
|
|
Recent market rumors indicate that Meta is negotiating to deploy Google's seventh-generation TPU "Ironwood" in its data centers by 2027, with procurement potentially reaching tens of billions of US dollars. This move signals confidence that Google will become a leading ASIC chip supplier, challenging Nvidia's dominance and securing the second spot in the AI accelerator market....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
11.11.25 - 16:06
|
Can Google’s Ironwood TPU Dethrone Nvidia’s AI Empire? (24/7 Wall St.)
|
|
|
The artificial intelligence (AI) boom has fueled explosive growth for Nvidia (NASDAQ:NVDA), with its graphics processing units commanding the lion's share of the market for training and running large language models. This success has lured numerous companies into the fray, from startups to tech giants, all vying for a piece of the lucrative AI hardware ... Can Google's Ironwood TPU Dethrone Nvidia's AI Empire?
The post Can Google's Ironwood TPU Dethrone Nvidia's AI Empire? appeared first on 24/7 Wall St.....
|
|
|
|
|
|
|
|
|
10.11.25 - 13:06
|
Ironwood Pharmaceuticals Reports Strong Third Quarter 2025 Results; Raises Full Year 2025 Financial Guidance (Business Wire)
|
|
|
– LINZESS® (linaclotide) U.S. net sales of $315 million in Q3 2025, an increase of 40% year-over-year; EUTRx demand growth increased 12% year-over-year –
– GAAP net income of $40 million and adjusted EBITDA of $82 million in Q3 2025; ended Q3 2025 with $140 million in cash and cash equivalents –
– Raises full-year 2025 LINZESS U.S. net sales guidance to $860 - $890 million; total revenue guidance to $290 - $310 million and adjusted EBITDA guidance to greater than $135 million –
– FDA approves LINZESS as the first drug for the treatment of children 7 years and older with irritable bowel syndrome with constipation (IBS-C) –BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today reported its third quarter 2025 results and recent business performance.
“LINZESS delivered a strong third-quarter performance, driven by accelerated d...
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
